Loading

wait a moment

Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism: Discussion

Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism: DiscussionIn this study, the CTLA-4 promoter ( — 318 C/T) polymorphism was found to be associated with asthma severity, but not with asthma, atopy, or bronchial hyperresponsiveness. The CTLA-4 exon 1 (+ 49 A/G) polymorphism was shown to be associated with bronchial hyperresponsiveness, but not with asthma, atopy, or asthma severity. From these results, it appears that the CTLA-4 gene may not be a susceptibility gene, but rather a disease-modifying gene that can modify the asthma phenotype.
There is also increasing evidence that CTLA-4 polymorphisms confer susceptibility to several autoimmune disorders buy allegra online buy allegra online. In particular, the exon 1 (+49 A/G) polymorphism has been found to be associated with type 1 diabetes, Graves disease, DR4-positive rheumatoid arthritis, multiple sclerosis, group and 20.4% in the severe group, and this association between severe asthma and the T allele was significant (p = 0.037). Asthma severity was determined according to the 1997 Expert Panel Report 2, which included various clinical parameters, such as the degree and frequency of symptoms, the frequency of exacerbation, FEV1, and PEF, Therefore, it is difficult to explain how the promoter ( — 318 C/T) T allele affects asthma severity. However, it may be useful as a genetic marker of severe asthma. Early recognition of infants at risk for severe asthma by determination of their CTLA-4 promoter (—318 C/T) T allele followed by close medical follow-up and early environmental or pharmacologic intervention may delay, attenuate, or prevent the progression of disease. In adults identified as “at risk” for severe asthma at the time of diagnosis, closer medical follow-up and early institution of therapy may alter their outcomes.